banner2

Getting started
N-1-Boc-2-Methylpiperazine CAS 120737-78-2

N-1-Boc-2-Methylpiperazine CAS 120737-78-2 - China Factory, Suppliers, Manufacturers

N-1-Boc-2-Methylpiperazine CAS 120737-78-2, , , ,. The product will supply to all over the world, such as Europe, America, Australia,, ,, .

Related Products

1-Boc-2-Methylpiperazine CAS 120737-78-2 Purity 98.0 (GC) Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — 1-Boc-2-Methylpiperazine CAS 120737-78-2 Purity >98.0% (GC)
Read More

Z-HomoPhe-OH CAS 127862-89-9 Assay ≥98.0% (HPLC)

Z-Ser-OH CAS 1145-80-8 N-Cbz-L-Serine Assay ≥99.0% (HPLC)

Z-Hyp-OH CAS 13504-85-3 Purity ≥99.0% (HPLC)

N-Cbz-N-Methyl-L-Isoleucine CAS 42417-66-3 Purity ≥98.0% (HPLC)

D-2-Cyanophenylalanine CAS 263396-41-4 Assay ≥98.0% (HPLC)

D-3-Cyanophenylalanine CAS 263396-43-6 Assay ≥98.0% (HPLC)

banner1

Top Selling Products

Related Blog
Reviews

The third Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical Innovation Technology and Market Access Summit forum November 19 to 21, 2021

The third Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical Innovation Technology and Market Access Summit forum November 19 to 21, 2021 As the world’s second largest medical market, ...
The 3rd China International Biological & Chemical Pharmaceutical Industry Conference

The 3rd CMC-China 2021 Time: September 29-30, 2021 Exhibition Venue: C-D Hall, Suzhou International Expo Center, Suzhou City, JIangsu Province, China. Synergy of Centralized China’s Drug Volume-ba...
New COVID treatments offer hope

Scientists around the world have made promising breakthroughs in developing a cure for COVID-19. Among new developments include antiviral pills and antibody compounds. As more countries look to ado...
The 87th China International Pharmaceutical Apis/Intermediates/Packaging/Equipment Fair (API China) -Shanghai Ruifu Chemical Co., Ltd. will attend with customers.

Shanghai Ruifu Chemical Co., Ltd. will attend the The 87th China International Pharmaceutical Apis/Intermediates/Packaging/Equipment Fair (API China) with customers. The 87th China International ...
Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study

Friday, November 05, 2021 – 06:45am PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adult...
Focus on Cross Border Integration of Biomedicine and Chemical Materials, October 15, 2021

Focus on Cross Border Integration of Biomedicine and Chemical Materials: New Opportunities, New Technologies and New Models This forum focuses on the interdisciplinary and cutting-edge technologies...

2022.11.14 06:15:18
2022.09.30 03:52:10
2022.09.08 16:19:44
2022.08.03 02:25:21
2022.01.08 11:00:36
2021.11.18 06:40:52

related search